CAR-T therapy survivors monitored for Long-Term safety and survival
NCT ID NCT06906380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal is to better understand the long-term safety and effectiveness of this treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Novant Health Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Could bone marrow from deceased donors cure blood cancers?
- Engineered immune cells take aim at Hard-to-Treat leukemia
- New blood test may predict cancer relapse after transplant
- New hope for blood cancer patients: daily pill aims to prevent relapse without transplant